Moderna is a biotechnology company built around messenger RNA (mRNA) as a platform for vaccines and therapeutics. It became widely known for its COVID-19 vaccine and continues to develop candidates in infectious disease, oncology, and rare diseases using the same modular approach. The model centers on designing and manufacturing mRNA constructs that instruct cells to produce specific proteins. Much of its commercial identity remains tied to vaccine technology and pipeline expansion beyond pandemic products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 137 | — | -825 | — |
| Q3 2025 | 1,002 | — | -200 | — |
| Q4 2025 | 676 | — | -826 | — |
| Q1 2026 | 389 | — | -1,343 | — |
| Q2 2026 | 143 | 4.4% | -782 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Intuit Inc. (INTU), Cintas Corporation (CTAS), Mondelez International, Inc. (MDLZ), DoorDash, Inc. (DASH), Regeneron Pharmaceuticals, Inc. (REGN), NetEase, Inc. (NTES)